Lilly would be more interested buying rspi's compound into their organization, rather than go to a competitor, and while rspi is more needful of cash, Lilly might get it as cheap as ever if they move swiftly?
A larger pharma could buy out the whole company for $6.6 million/.01 per share and have the entire pipeline!
Now hopefully the company is looking for a better deal than that because it's worth much more! Minimum 25 million imho. The value of one drug.
Market Data 
Markets 
AI
